Myong Cheol Lim
- Obstetrics and Gynecology top 0.2%
- Endometrial and Cervical Cancer Treatments 93
- Uterine Myomas and Treatments 26
- Reproductive Medicine top 0.2%
- Ovarian cancer diagnosis and treatment 134
- Endometriosis Research and Treatment 28
- Oncology top 2%
- PARP inhibition in cancer therapy 29
- Surgery top 2%
- Intraperitoneal and Appendiceal Malignancies 37
- Epidemiology top 5%
- Cervical Cancer and HPV Research 48
-
- BRCA gene mutations in cancer 30
- Co-authors
- Sang‐Soo SeoSokbom KangSang‐Yoon ParkHeon Jong YooYoung‐Joo WonJae‐Weon KimYong Jung SongJong Ha Hwang
- Partner nations
- South KoreaUnited StatesUnited Kingdom
In The Last Decade
Myong Cheol Lim
254 papers receiving 4.1k citations
Hit Papers
Peers
Comparison fields: 5 of 126
- Obstetrics and Gynecology 1.8k
- Reproductive Medicine 1.9k
- Oncology 1.1k
- Surgery 1.2k
- Epidemiology 820
Countries citing papers authored by Myong Cheol Lim
This map shows the geographic impact of Myong Cheol Lim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Myong Cheol Lim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Myong Cheol Lim more than expected).
Fields of papers citing papers by Myong Cheol Lim
This network shows the impact of papers produced by Myong Cheol Lim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Myong Cheol Lim. The network helps show where Myong Cheol Lim may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Myong Cheol Lim, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2024 | 2 | |
| 3 | 2024 | 4 | |
| 4 | 2024 | 1 | |
| 5 | 2024 | 2 | |
| 6 | 2024 | 1 | |
| 7 | 2023 | 2 | |
| 8 | 2023 | 4 | |
| 9 | 2023 | 0 | |
| 10 | 2023 | 3 | |
| 11 | 2023 | 1 | |
| 12 | 2023 | 3 | |
| 13 | 2022 | 1 | |
| 14 | 2022 | 15 | |
| 15 | 2021 | 2 | |
| 16 | 2021 | 4 | |
| 17 | 2021 | 6 | |
| 18 | 2020 | 5 | |
| 19 | 2019 | 10 | |
| 20 | 2015 | 16 |
About Myong Cheol Lim
Myong Cheol Lim is a scholar working on Reproductive Medicine, Obstetrics and Gynecology and Oncology, having authored 268 papers that have together received 4.1k indexed citations. Recurring topics across this work include Ovarian cancer diagnosis and treatment (134 papers), Endometrial and Cervical Cancer Treatments (93 papers), Cervical Cancer and HPV Research (48 papers), Intraperitoneal and Appendiceal Malignancies (37 papers), BRCA gene mutations in cancer (30 papers), PARP inhibition in cancer therapy (29 papers), Endometriosis Research and Treatment (28 papers) and Uterine Myomas and Treatments (26 papers). The work is most often cited by research in Obstetrics and Gynecology (1.8k citations), Reproductive Medicine (1.9k citations) and Oncology (1.1k citations). Myong Cheol Lim has collaborated with scholars based in South Korea, United States and United Kingdom. Frequent co-authors include Sang‐Soo Seo, Sokbom Kang, Sang‐Yoon Park, Sang‐Yoon Park, Heon Jong Yoo, Young‐Joo Won, Jae‐Weon Kim, Yong Jung Song, Jong Ha Hwang and Se Ik Kim. Their work appears in journals such as Nature Communications, Journal of Clinical Oncology and PLoS ONE.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.